NCT01631357

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 96 (actual)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell lung cancer

Detailed description

1. Phase II/III study, 2. Randomized, multicenter, open-label study, 3. Evaluated the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy compared with chemotherapy in patients with stage IIIb-IV squamous non-small-cell lung cancer

Conditions

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	CIK cell	CIK cell injection
DRUG	Gemcitabine Injection	Gemcitabine injection
DRUG	Cisplatin injection	Cisplatin injection

Timeline

• Start date: 2014-12-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2012-06-29
• Last updated: 2019-11-05

Locations

1 site across 1 country: China